MedTrace Logo

PEACH Trial: Prescribed Exercise After Chemotherapy

NCT01030887 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2011-08-15

No results posted yet for this study

Summary

Many cancer survivors suffer symptoms such as fatigue and dyspnea which may persist for years or months after their chemotherapy has finished. Despite the known benefits of exercise and its potential to address many of the symptoms after cancer, the type of practical exercise programme which best suits this population is not known.

Many exercise programmes performed in cancer survivors take place over many weeks or months and include people with specific types of cancer. Such programmes may therefore not be suitable for the majority of cancer survivors and would pose serious practical difficulties with high drop-out rates and expensive resource consumption if they were extended into clinical practice.

We propose to run an 8-week exercise intervention in a mixed cancer population.

Hypothesis: A brief, individually tailored 8-week intervention will increase fitness and improve other physical symptoms in a mixed cancer survivor population after chemotherapy.

Conditions

Interventions

BEHAVIORAL

Exercise programme

Moderate intensity exercise

Sponsors & Collaborators

  • Health Research Board, Ireland

    collaborator OTHER

  • University of Dublin, Trinity College

    lead OTHER

Principal Investigators

  • Dearbhaile O' Donnell, MD · St. James's Hospital, Dublin, Ireland

  • Juliette Hussey, PhD · Trinity College Dublin, Ireland

  • Julie M Walsh, MSc · University of Dublin, Trinity College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01030887 on ClinicalTrials.gov